-
1.发明申请公开(公告)号：US20070178063A1
公开(公告)日：2007-08-02
申请号：US11539511
申请日：2006-10-06
Applicant: Wayne Kindsvogel , Steven Hughes , Richard Holly , Christopher Clegg , Donald Foster , Rebecca Johnson , Mark Heipel , Pallavur Sivakumar
Inventor： Wayne Kindsvogel , Steven Hughes , Richard Holly , Christopher Clegg , Donald Foster , Rebecca Johnson , Mark Heipel , Pallavur Sivakumar
IPC: A61K38/20 , A61K39/395
CPC classification number: C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
Abstract: Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
Abstract translation: 描述了通过用IL-21共同施用治疗性单克隆抗体来治疗癌症的方法。 可以使用的示例性单克隆抗体是利妥昔单抗，曲妥珠单抗和抗CTLA-4抗体。 联合治疗的增强的抗肿瘤剂对于单克隆治疗顽固性，用单克隆抗体治疗后复发或增强的IL-21抗肿瘤作用降低与使用单克隆抗体治疗相关的毒性的患者群体特别有用。
-
2.发明申请公开(公告)号：US20050265966A1
公开(公告)日：2005-12-01
申请号：US11134489
申请日：2005-05-20
Applicant: Wayne Kindsvogel , Steven Hughes , Richard Holly , Christopher Clegg , Donald Foster , Rebecca Johnson , Mark Heipel , Pallavur Sivakumar
Inventor： Wayne Kindsvogel , Steven Hughes , Richard Holly , Christopher Clegg , Donald Foster , Rebecca Johnson , Mark Heipel , Pallavur Sivakumar
IPC: A61K38/20 , A61K39/395 , C07K16/28 , C07K16/32
CPC classification number: C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
Abstract: Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
Abstract translation: 描述了通过用IL-21共同施用治疗性单克隆抗体来治疗癌症的方法。 可以使用的示例性单克隆抗体是利妥昔单抗，曲妥珠单抗和抗CTLA-4抗体。 联合治疗的增强的抗肿瘤剂对于单克隆治疗顽固性，用单克隆抗体治疗后复发或增强的IL-21抗肿瘤作用降低与使用单克隆抗体治疗相关的毒性的患者群体特别有用。
-
公开(公告)号：US20070122382A1
公开(公告)日：2007-05-31
申请号：US11539493
申请日：2006-10-06
Applicant: Wayne Kindsvogel , Steven Hughes , Richard Holly , Christopher Clegg , Donald Foster , Rebecca Johnson , Mark Heipel , Pallavur Sivakumar
Inventor： Wayne Kindsvogel , Steven Hughes , Richard Holly , Christopher Clegg , Donald Foster , Rebecca Johnson , Mark Heipel , Pallavur Sivakumar
IPC: A61K39/395 , A61K38/20
CPC classification number: C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
Abstract: Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
-
公开(公告)号：US20070048264A1
公开(公告)日：2007-03-01
申请号：US11539479
申请日：2006-10-06
Applicant: Wayne Kindsvogel , Steven Hughes , Richard Holly , Christopher Clegg , Donald Foster , Rebecca Johnson , Mark Heipel , Pallavur Sivakumar
Inventor： Wayne Kindsvogel , Steven Hughes , Richard Holly , Christopher Clegg , Donald Foster , Rebecca Johnson , Mark Heipel , Pallavur Sivakumar
IPC: A61K38/20 , A61K39/395
CPC classification number: C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
Abstract: Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
-
-
-
Search Results
4
records
(took 0.094 seconds)
